Corcept Therapeutics reported $114.72M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Alaunos Therapeutics USD -952K 60K Jun/2026
ANI Pharmaceuticals USD 51.84M 12M Sep/2026
Ardelyx USD -10.39M 20.29M Jun/2026
Aurora Cannabis CAD -3.17M 10.29M Jun/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Canopy Growth CAD -2.03M 143.62M Jun/2026
Corcept Therapeutics USD 114.72M 73.42M Sep/2026
Eli Lilly USD 13.09B 635M Sep/2026
J&J USD 6.47B 1B Sep/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Merck USD 7.33B 6.49B Sep/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novartis USD 5.14B 411M Sep/2026
Novartis USD 1.78B 2.4B Sep/2026
Omeros USD -48.15M 7.25M Sep/2023
Pacira USD 2.57B 2.56B Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
TG Therapeutics USD 85.9M 64.22M Sep/2026